$2.06 EPS Expected for Johnson & Johnson (JNJ) as of July, 17

June 27, 2018 - By Ronnie Lemelle

Johnson & Johnson (NYSE:JNJ) Corporate Logo
During Q1 2018 the big money sentiment increased to 0.93. That’s change of 0.06, from 2017Q4’s 0.87. 63 investors sold all, 831 reduced holdings as Johnson & Johnson ratio improved. 720 increased stakes while 111 funds bought stakes. Funds hold 1.71 billion shares thus 0.80% less from 2017Q4’s 1.72 billion shares.
Berson & Corrado Inv Advsrs Lc holds 3,330 shs. 7,468 were reported by Todd Asset Mngmt Ltd Llc. Harbour Invest Mngmt Limited Liability Corporation invested 2.03% in Johnson & Johnson (NYSE:JNJ). Needelman Asset has 10,310 shs. Financial Advisory Group reported 5,976 shs. Wedgewood Investors Pa owns 1.29% invested in Johnson & Johnson (NYSE:JNJ) for 11,808 shs. Cincinnati Indemnity Communications holds 13.49% in Johnson & Johnson (NYSE:JNJ) or 25,000 shs. Horizon Investment Service Llc holds 0.18% of its capital in Johnson & Johnson (NYSE:JNJ) for 3,087 shs. Inverness Counsel Ltd Limited Liability Company Ny has 98,889 shs for 0.76% of their capital. Cortland Inc Mo holds 0.09% in Johnson & Johnson (NYSE:JNJ) or 4,014 shs. 29,153 are held by Bath Savings Tru. Northwest Inv Counselors Ltd Liability Company reported 35,411 shs stake. Intact Inv Mngmt reported 51,300 shs. The Texas-based Eagle Global Advsrs Limited Co has invested 0.34% in Johnson & Johnson (NYSE:JNJ). Prospector Prns Lc has invested 1.17% in Johnson & Johnson (NYSE:JNJ).

Johnson & Johnson had 1 sale and 0 buys since February 15, 2018. This’s net activity of $20.17 million.

Johnson & Johnson (NYSE:JNJ)’s earnings release is anticipated by WallStreet on July, 17, RTT reports. Analysts expect change of 12.57 % or $0.23 from previous year’s $1.83 earnings per share compared to current’s $2.06 earnings per share. The profit will be $5.53 billion for JNJ if $2.06 earnings per share becomes true. Wall Street predicts 0.00 % EPS growth as of July, 17. Ticker’s shares touched $121.74 during the last trading session after 0.50% change.Johnson & Johnson has volume of 311,961 shares. Since June 27, 2017 JNJ has declined 4.75% and is downtrending. JNJ underperformed the S&P500 by 17.32%.

Johnson & Johnson (NYSE:JNJ) Ratings Coverage

A total of 10 analysts rate Johnson & Johnson (NYSE:JNJ) as follows: 5 “Buy”, 4 “Hold” and 1 “Sell”. Тherefore 50% are bullish. (NYSE:JNJ) has 19 ratings reports on Jun 27, 2018 according to StockzIntelligence. The stock rating was maintained by Jefferies with “Buy” on Friday, March 23. On Wednesday, April 18 the rating was maintained by Deutsche Bank with “Buy”. On Tuesday, February 27 Citigroup maintained the shares of JNJ in report with “Neutral” rating. On Tuesday, February 6 Wells Fargo maintained the shares of JNJ in report with “Buy” rating. On Tuesday, January 23 the rating was maintained by BTIG Research with “Sell”. On Tuesday, January 16 Jefferies maintained the shares of JNJ in report with “Buy” rating. On Wednesday, April 18 the stock of Johnson & Johnson (NYSE:JNJ) earned “Buy” rating by Leerink Swann. On Friday, April 20 the firm earned “Outperform” rating by Credit Suisse. The company rating was maintained by Stifel Nicolaus on Wednesday, January 24. In Monday, February 26 report Jefferies maintained the stock with “Buy” rating.

Johnson & Johnson, together with its subsidiaries, researches and develops, makes, and sells various products in the health care field worldwide.The company has $326.53 billion market cap. It operates through three divisions: Consumer, Pharmaceutical, and Medical Devices.The P/E ratio is 269.34. The Consumer segment offers baby care products under the JOHNSONÂ’S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSONÂ’S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

A couple more Johnson & Johnson (NYSE:JNJ) news were released by: Forbes.com which released on June 20, 2018 “What Are Johnson & Johnson’s Key Sources Of Revenue?”, also Fool.com on June 20, 2018 released “Forget Johnson & Johnson: Here Are 2 Better Dividend Stocks”, the next Seekingalpha.com is “How Do You Feel About Johnson & Johnson?: Part IV – Today’s Editors’ Picks” on June 01, 2018. Seekingalpha.com has article titled “Buy Johnson & Johnson”.

Johnson & Johnson (NYSE:JNJ) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.